Last reviewed · How we verify
NCT03420872
Nutrient Mixtures and Neurodevelopment
trial testing Nutrient mixtures in Neurodevelopment in 329 participants. Completed in 15 August 2018.
15 August 2018
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 329 |
| Start date | 15 September 2006 |
| Primary completion | 15 August 2018 |
| Estimated completion | 15 August 2018 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Nutrient mixtures
Conditions studied
- Neurodevelopment — all drugs for Neurodevelopment →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
Adults 18 to 44, any sex, with Neurodevelopment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Adequate levels of beneficial nutrients are important for neurodevelopment. Although, nutrients are ingested in combination, considering nutrients as a mixture has not been studied with respect to health, such as neurodevelopment. Objective: To examine the impact of prenatal and childhood nutrition mixtures on neurodevelopment. Design: Participants included mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City. Prenatal and child nutrition profiles were assessed among 65 and 329 children respectively by analyzing components of a food frequency questionnaire. Child neurodevelopmental outcomes at 4-6 years of age were measured using the McCarthy Scales of Children's Abilities (MSCA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03420872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodevelopment
Currently open trials in the same condition.
- NCT06823492 — Investigating the Impacts of Early Life Experience on the Brain & Behaviour · recruiting
- NCT03633162 — Maternal Grandmothers in the Born in Guangzhou Cohort Study · recruiting
- NCT03331133 — Twins Born in Guangzhou · recruiting
- NCT02526901 — The Born in Guangzhou Cohort Study (BIGCS) · recruiting
- NCT03668327 — Preterm Birth Cohort Study in Guangzhou · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03420872 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 14 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03420872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing